Searching for optimized follow-up timing after radiofrequency ablation of benign thyroid nodules: Systematic review and Meta-analysis.
메타분석
1/5 보강
[OBJECTIVE] The primary objective of this study was to determine the optimal ultrasound(US) follow-up timing after radiofrequency ablation(RFA) for benign thyroid nodules(BTNs),conducting a systematic
- p-value p < 0.01
- 95% CI 35.06-50.87
- 연구 설계 systematic review
APA
Wolde Sellasie S, Deandrea M, et al. (2026). Searching for optimized follow-up timing after radiofrequency ablation of benign thyroid nodules: Systematic review and Meta-analysis.. European journal of radiology, 195, 112529. https://doi.org/10.1016/j.ejrad.2025.112529
MLA
Wolde Sellasie S, et al.. "Searching for optimized follow-up timing after radiofrequency ablation of benign thyroid nodules: Systematic review and Meta-analysis.." European journal of radiology, vol. 195, 2026, pp. 112529.
PMID
41289722 ↗
Abstract 한글 요약
[OBJECTIVE] The primary objective of this study was to determine the optimal ultrasound(US) follow-up timing after radiofrequency ablation(RFA) for benign thyroid nodules(BTNs),conducting a systematic review and meta-analysis of published data on volume reduction rate(VRR) outcomes across different follow-up intervals.
[DESIGN AND METHODS] A systematic search of articles published up to January 17, 2025 identified studies reporting RFA treatment for BTNs. Characteristics of the study design, BTNs cohorts, and outcomes of interest(VRR at 1,3,6 and 12 months of follow up) were extracted. Statistical analysis included a random-effects meta-analysis, assessment of heterogeneity with use of the I statistic, and meta-regression and subgroup analyses to explore potential sources of heterogeneity.
[RESULTS] Twenty-nine studies comprising 3033 BTNs were included.The pooled VRRs at 1,3,6, and 12 months post-RFA were 42.96 %(95 %CI:35.06-50.87),61.80 %(95 %CI:57.66-65.95),69.89 %(95 %CI:67.08-72.69), and 77.86 %(95 %CI:75.89-79.67),respectively. Meta-regression analysis using baseline mean BTN volume revealed an inverse correlation with VRR at both 6 and 12 months(p < 0.01).Small-volume group(<15 mL):Significant changes in VRR were observed between 1-[45.76 %(95 %CI:38.22-53.29)],3-[63.91 %(95 %CI:58.84-68.99)], 6-[74.59 %(95 %CI:71.08-78.11)], and 12-month[81.42 %(95 %CI:78.56-84.29)] follow-ups.Medium-volume group(15-30 mL):Significant changes were noted between 1[47.09 %(95 %CI:40.84-53.34)] and 3 months[63.05 %(95 %CI:60.14-65.96)],and between 6[67.91 %(95 %CI:65.13-70.70)] and 12 months[75.61 %(95 %CI:71.79-79.45)].Large-volume group(≥30 mL):A significant change in VRR was observed only between the 6-[59 %(95 %CI:54.20-63.81)] and 12-month[69.32 %(95 %CI:64.97-73.68)]follow-ups.
[CONCLUSION] A streamlined follow-up schedule consisting of two US assessments-an early evaluation at 1-3 months and a final evaluation at 12 months-can be sufficient for most patients. These strong findings can guide clinical decision-making, provide a benchmark for RFA efficacy, and support the optimization of healthcare resources.
[DESIGN AND METHODS] A systematic search of articles published up to January 17, 2025 identified studies reporting RFA treatment for BTNs. Characteristics of the study design, BTNs cohorts, and outcomes of interest(VRR at 1,3,6 and 12 months of follow up) were extracted. Statistical analysis included a random-effects meta-analysis, assessment of heterogeneity with use of the I statistic, and meta-regression and subgroup analyses to explore potential sources of heterogeneity.
[RESULTS] Twenty-nine studies comprising 3033 BTNs were included.The pooled VRRs at 1,3,6, and 12 months post-RFA were 42.96 %(95 %CI:35.06-50.87),61.80 %(95 %CI:57.66-65.95),69.89 %(95 %CI:67.08-72.69), and 77.86 %(95 %CI:75.89-79.67),respectively. Meta-regression analysis using baseline mean BTN volume revealed an inverse correlation with VRR at both 6 and 12 months(p < 0.01).Small-volume group(<15 mL):Significant changes in VRR were observed between 1-[45.76 %(95 %CI:38.22-53.29)],3-[63.91 %(95 %CI:58.84-68.99)], 6-[74.59 %(95 %CI:71.08-78.11)], and 12-month[81.42 %(95 %CI:78.56-84.29)] follow-ups.Medium-volume group(15-30 mL):Significant changes were noted between 1[47.09 %(95 %CI:40.84-53.34)] and 3 months[63.05 %(95 %CI:60.14-65.96)],and between 6[67.91 %(95 %CI:65.13-70.70)] and 12 months[75.61 %(95 %CI:71.79-79.45)].Large-volume group(≥30 mL):A significant change in VRR was observed only between the 6-[59 %(95 %CI:54.20-63.81)] and 12-month[69.32 %(95 %CI:64.97-73.68)]follow-ups.
[CONCLUSION] A streamlined follow-up schedule consisting of two US assessments-an early evaluation at 1-3 months and a final evaluation at 12 months-can be sufficient for most patients. These strong findings can guide clinical decision-making, provide a benchmark for RFA efficacy, and support the optimization of healthcare resources.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.